Zoetis Inc. (ZTS) Earnings Call Transcripts

Zoetis Inc.'s Latest Earnings Call - September 14, 2026

In the third quarter of fiscal year 2026, Zoetis Inc. reported a significant recalibration of its operational revenue guidance, now projecting a decline of 3% to 1%, down from a previous forecast of 2% to 5%. This adjustment reflects competitive pressures and a declining pet care market, which management acknowledged for the first time. The company emphasized confidence in its innovation pipeline and long-term growth potential despite current challenges, with CEO Kristin Peck stating, "this is cyclical, it's not structural," indicating optimism for recovery in the pet care segment.

Reported metrics

Guidance from management

Management maintained confidence in the long-term growth potential driven by the innovation pipeline, with updates expected in November. However, they did not provide specific guidance for 2027, indicating a cautious approach to future projections.

What management said

Sure. I've spent a lot of time coming in, getting up to speed on guidance, obviously, since there have been quite a few short-term dynamics here. And what I would say is we're confident in the guidance that we've shared. We made certain assumptions about the market no improvement in the market and things of that nature. The market is evolving as we expected. So we feel good about the guidance, and we look forward to ...

There's different -- and again, we have different strategy. I mean what's different, again, about parasiticide is we can target who -- where are we the primary. Obviously, that's not a [indiscernible] versus where. So it's a very different competitive market there where there's been some established players actually for a long time. And that's, as you know, been extremely competitive since the very beginning, paras -...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of the pricing strategy amidst competitive pressures and the declining pet care market. There were questions about the timing of market recovery and the effectiveness of current promotional tactics in stabilizing market share.

Main topics on the call

• Revenue Guidance Adjustment — Zoetis has recalibrated its operational revenue guidance to a decline of 3% to 1%, down from a previous range of 2% to 5%. CEO Kristin Peck noted, "we saw a declining pet care market," highlighting the competitive dynami...
• Market Dynamics and Competitive Pressure — Management acknowledged that the pet care market is experiencing unprecedented declines, with visits down 6.7%. Peck stated, "we did get a third entrant overall in derm against Apoquel," which has intensified competitive...
• Innovation Pipeline and Long-term Growth — Despite current challenges, management remains optimistic about the innovation pipeline, particularly in chronic kidney disease (CKD) and oncology. Peck mentioned, "we're super excited about launching that innovation pip...
• Pricing Strategy — Zoetis is implementing targeted pricing strategies to preserve volume amidst competitive pressures, with net price realization expected to be negative 1% to negative 2% for the year. Peck emphasized that these actions ar...

Read the full Zoetis Inc. transcript (September 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 79 Zoetis Inc. earnings call transcripts on record, spanning January 15, 2020 to September 14, 2026. Based on this history, Zoetis Inc. reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ZTS

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

79

First call

January 15, 2020

Most recent

September 14, 2026

Reporting cadence

quarterly